Should I buy or sell Pliant Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLRX shares. View PLRX analyst ratings or view top-rated stocks .

What is Pliant Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued 1-year price objectives for Pliant Therapeutics' shares. Their PLRX share price targets range from $38.00 to $63.00. On average, they predict the company's stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 291.4% from the stock's current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts .

How have PLRX shares performed in 2024?

Pliant Therapeutics' stock was trading at $18.11 at the start of the year. Since then, PLRX stock has decreased by 30.9% and is now trading at $12.52. View the best growth stocks for 2024 here .

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PLRX earnings forecast .

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.06. The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $2.50 million.

What ETFs hold Pliant Therapeutics' stock?

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE) , CrowdStrike (CRWD) , Trevena (TRVN) , AbbVie (ABBV) , Abbott Laboratories (ABT) , Archer-Daniels-Midland (ADM) , Akero Therapeutics (AKRO) , Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN) .

When did Pliant Therapeutics IPO?

Pliant Therapeutics (PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.48%). Insiders that own company stock include Bernard Coulie , Eric Lefebvre , Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. View institutional ownership trends .

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PLRX

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free PLRX Stock Alerts

$12.52

+0.33 (+2.71%)

(As of 04/19/2024 ET)

Compare

Today's Range: $12.00
▼
$12.55
50-Day Range: $12.19
▼
$17.27
52-Week Range: $12.00
▼
$30.85

Volume: 306,184 shs
Average Volume: 386,417 shs
Market Capitalization: $754.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $49.00

Get Pliant Therapeutics alerts:

Pliant Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 291.4% Upside
$49.00 Price Target
Short Interest: Bearish
12.38% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.18
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.77) to ($3.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

336th out of 911 stocks

Pharmaceutical Preparations Industry

145th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Pliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Pliant Therapeutics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
12.38% of the outstanding shares of Pliant Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Pliant Therapeutics has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Pliant Therapeutics has recently increased by 6.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Pliant Therapeutics does not currently pay a dividend.
Dividend Growth
Pliant Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Pliant Therapeutics is -0.73.

1.8

News and Social Media Coverage

News Sentiment
Pliant Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Pliant Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
12 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.60% of the stock of Pliant Therapeutics is held by insiders.
Percentage Held by Institutions
97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($2.77) to ($3.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pliant Therapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pliant Therapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pliant Therapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad American Alternative

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PLRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PLRX Stock News Headlines

April 17, 2024 | americanbankingnews.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts

April 11, 2024 | americanbankingnews.com

Pliant Therapeutics (NASDAQ:PLRX) Earns "Buy" Rating from Needham & Company LLC

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

April 9, 2024 | investing.com

Pliant Therapeutics Inc (PLRX)

April 2, 2024 | globenewswire.com

Pliant Therapeutics to Participate in Upcoming Investor Events

March 27, 2024 | globenewswire.com

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

March 17, 2024 | finance.yahoo.com

PLRX Oct 2024 30.000 call

March 16, 2024 | finance.yahoo.com

PLRX Oct 2024 7.500 put

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

March 12, 2024 | finanznachrichten.de

Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

March 12, 2024 | globenewswire.com

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

March 11, 2024 | finance.yahoo.com

PLRX Jul 2024 20.000 call

March 8, 2024 | markets.businessinsider.com

Pliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid Financials

March 6, 2024 | ca.finance.yahoo.com

PLRX Jul 2024 10.000 put

February 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Pliant Therapeutics Amid Promising Drug Pipeline and Financial Stability

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Pliant Therapeutics on Promising Pipeline and Strong Financials

February 28, 2024 | markets.businessinsider.com

Pliant Therapeutics (PLRX) Receives a Buy from TD Cowen

February 27, 2024 | globenewswire.com

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

February 26, 2024 | globenewswire.com

Pliant Therapeutics to Participate in Upcoming Investor Conferences

February 23, 2024 | finance.yahoo.com

PLRX Mar 2024 10.000 put

February 18, 2024 | morningstar.com

Pliant Therapeutics Inc Ordinary Shares PLRX

February 18, 2024 | finance.yahoo.com

PLRX Mar 2024 25.000 call

February 8, 2024 | markets.businessinsider.com

Buy Rating on Pliant Therapeutics: Positive Outlook on Bexotegrast Despite Investor Concerns

February 7, 2024 | markets.businessinsider.com

Buy Rating on Pliant Therapeutics: Promising IPF Drug Outlook Overcomes PSC Concerns

February 6, 2024 | msn.com

Pliant Therapeutics Achieves Success in Liver Disease Trial

February 5, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know

February 5, 2024 | msn.com

Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?

See More Headlines

Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PLRX
CUSIP: N/A
CIK: 1746473
Web: pliantrx.com
Phone: 650-481-6770
Fax: N/A
Employees: 158
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $49.00
High Stock Price Target: $63.00
Low Stock Price Target: $38.00
Potential Upside/Downside: +291.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-161,340,000.00
Net Margins: N/A
Pretax Margin: -10,211.14%
Return on Equity: -31.15%
Return on Assets: -29.00%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 17.72
Quick Ratio: 17.72

Sales & Book Value

Annual Sales: $1.58 million
Price / Sales: 477.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.91 per share
Price / Book: 1.58

Miscellaneous

Outstanding Shares: 60,240,000
Free Float: 56,866,000
Market Cap: $754.20 million
Optionable: Optionable
Beta: 1.12

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Bernard Coulie M.B.A. (Age 57)
M.D., Ph.D., President, CEO & Director
Comp: $1.06M
Dr. Keith Lamont Cummings M.B.A. (Age 47)
M.D., Chief Financial Officer
Comp: $662.34k
Mr. Mike Ouimette J.D. (Age 51)
General Counsel & Corporate Secretary
Comp: $591.05k
Mr. Johannes P. Hull (Age 49)
Chief Business Officer
Comp: $631.64k
Dr. Éric Lefebvre M.D. (Age 60)
Chief Medical Officer
Comp: $763.49k
Dr. Rik Derynck
Scientific Founder & Member of Scientific Advisory Board
Mr. Dean Sheppard M.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Bill DeGrado Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Hal Chapman M.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Craig D. Muir
Interim Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings or view top-rated stocks.
What is Pliant Therapeutics' stock price target for 2024?: 9 Wall Street research analysts have issued 1-year price objectives for Pliant Therapeutics' shares. Their PLRX share price targets range from $38.00 to $63.00. On average, they predict the company's stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 291.4% from the stock's current price.
View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts.
How have PLRX shares performed in 2024?: Pliant Therapeutics' stock was trading at $18.11 at the start of the year. Since then, PLRX stock has decreased by 30.9% and is now trading at $12.52.
View the best growth stocks for 2024 here.
When is Pliant Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PLRX earnings forecast.
How were Pliant Therapeutics' earnings last quarter?: Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.06. The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $2.50 million.
What ETFs hold Pliant Therapeutics' stock?: ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Pliant Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).
When did Pliant Therapeutics IPO?: Pliant Therapeutics (PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.
Who are Pliant Therapeutics' major shareholders?: Pliant Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.48%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends.
How do I buy shares of Pliant Therapeutics?: Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PLRX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

Pliant Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Pliant Therapeutics Stock (NASDAQ:PLRX)

PLRX Stock Price History

PLRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PLRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™